We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel POC Troponin Assay Rules Out Acute MI

By LabMedica International staff writers
Posted on 05 Nov 2018
Image: The i-STAT cardiac troponin I assay; healthcare professionals can obtain quantitative measurement of cardiac troponin I (cTnI) in ten minutes without leaving the patient\'s side (Photo courtesy of Abbott Point of Care).
Image: The i-STAT cardiac troponin I assay; healthcare professionals can obtain quantitative measurement of cardiac troponin I (cTnI) in ten minutes without leaving the patient\'s side (Photo courtesy of Abbott Point of Care).
More than seven billion diagnostic tests are run in the USA each year to help physicians make accurate, timely decisions about a person's medical treatment. Emergency department (ED) investigations of patients with suspected acute myocardial infarction (AMI) are time consuming, partly because of the turnaround time of laboratory tests.

Point-of-care diagnostic tests, that can often provide results within minutes, are used globally as hospitals face increased pressures to address overcrowding in emergency rooms and longer wait times. The goal of with-patient diagnostic tests is to deliver results with accuracy similar to the gold standard of high-sensitivity laboratory tests.

A team of scientists collaborating with Christchurch Hospital (Christchurch, New Zealand) evaluated 354 adults, including 255 (72.0%) men; mean age, 62 ± 12 years, who entered an emergency department with symptoms of acute coronary syndrome, such as a heart attack. Troponin concentrations were measured on ED arrival with both a novel point-of-care assay i-STAT TnI-Nx and a high-sensitivity troponin I assay, the Architect hs-cTnI.

The investigators reported that of 354 patients, 57 (16.1%) experienced an AMI. Eighty-five patients (24.0%) presented to the ED less than three hours after symptom onset. No difference was found between the area under the curve (AUC) of the TnI-Nx assay (0.975) and the hs-cTnI assay (0.970). A TnI-Nx assay result of less than 11 ng/L identified 201 patients (56.7%) as low risk, with sensitivity and a negative predictive value of 100%. In comparison, an hs-cTnI assay result of less than 3 ng/L identified 154 patients (43.5%) as low risk, with a sensitivity and a negative predictive value of 100%.

The authors concluded that a novel point-of-care troponin assay that can produce a result 15 minutes after blood sampling had comparable discrimination ability to an hs-cTnI assay for ruling out AMI after a single blood test. Use in the ED may facilitate earlier decision-making and could expedite the safe discharge of a large proportion of low-risk patients. Additional usefulness of this assay is likely to be found outside of the ED, such as in rural hospitals and general practices where there is limited rapid access to laboratory-based troponin assays. The study was published on October 17, 2018, in the journal JAMA Cardiology.

Related Links:
Christchurch Hospital

New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Hemodynamic System Monitor
OptoMonitor

Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more